This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bioniche Life Sciences Inc. Reacts To Canadian Federal Budget

BELLEVILLE, ON, March 26, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided its reaction to last week's Canadian Budget 2013.

The Company is encouraged to see the Canadian government expressing support for business innovation, to allow Canadian companies to become more competitive in global markets.

Federal Economic Development Agency for Southern Ontario

The Company was pleased to see the federal government's continuing investment in the Federal Economic Development Agency for Southern Ontario. As a southern Ontario-headquartered business, Bioniche Life Sciences Inc. has benefited from this program in the form of a $750,000 investment in the creation of a pilot-scale fermentation facility adjacent to the Company's Animal Health and Food Safety Vaccine Manufacturing Centre in Belleville, Ontario. As successful animal health or food safety vaccine candidates are identified and evaluated, they are brought into this new facility for development, scale-up and preparation for commercial-scale manufacturing.

"The Canadian government's renewed funding for this program, combined with an allocation for a new Advanced Manufacturing Fund in Ontario, is a positive sign for a manufacturing-oriented company like ours," said Mr. Graeme McRae, President & CEO, Bioniche Life Sciences Inc.

Fostering Business Innovation; Market Access is Critical

The Company was also pleased to see the federal government's plan to invest $121 million over two years in the National Research Council (NRC) to help the growth of innovative Canadian businesses. Bioniche Life Sciences Inc. has benefited from the NRC's Industrial Research Assistance Program (IRAP) for early-stage research and development projects. Continuing federal support for the NRC and for companies that invest in R&D leading to commercialization of Canadian science and the creation and retention of high-value jobs in Canada is very positive.

"Bioniche remains committed to commercializing new products from Canada - whether they be for animal health, human health or one health (addressing zoonotic diseases that affect humans)," added Mr. McRae. "Government support for innovative Canadian companies with a mission to take products through the development cycle and commercialize them from Canada is welcome and Bioniche will continue to strongly advocate for policies that support market access for its Canadian discoveries."

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and One Health. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs